(STE) STERIS - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 20.778m USD | Total Return: -13.2% in 12m

Sterilizers, Surgical Equipment, Contract Sterilization, Cleaning Chemistries

Total Rating 44

Safety 78

Buy Signal -0.57

Medical Devices
Industry Rotation: +6.2

Market Cap: 20.8B
Avg Turnover: 159M

Risk 3d forecast

Volatility23.7%

VaR 5^th Pctl4.05%

VaR vs Median3.71%

Reward TTM

Sharpe Ratio-0.66

Rel. Str. IBD14.4

Rel. Str. Peer Group34.4

Character TTM

Beta0.346

Beta Downside0.382

Hurst Exponent0.505

Drawdowns 3y

Max DD24.67%

CAGR/Max DD0.08

CAGR/Mean DD0.30

EPS (Earnings per Share)

EPS CAGR: 11.21%
EPS Trend: 82.3%

Last SUE: -0.22
Qual. Beats: 0

Revenue

Rev. CAGR: 8.83%
Rev. Trend: 81.4%

Last SUE: -0.04
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: STE STERIS

STERIS plc (NYSE: STE) is a global provider of infection prevention and sterilization solutions, primarily serving hospitals, medical device manufacturers, and pharmaceutical companies. The company operates through three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its portfolio includes cleaning chemistries, surgical equipment, contract sterilization services, and specialized water purification systems.

The business model relies heavily on a razor-and-blade strategy, where the installation of capital equipment like sterilizers and surgical tables creates a long-term recurring revenue stream through high-margin consumables and maintenance services. In the AST segment, STERIS benefits from high barriers to entry due to the significant regulatory requirements and capital intensity involved in operating gamma irradiation and ethylene oxide sterilization facilities.

Investors may find it useful to review ValueRay for deeper insights into the companys valuation and long-term performance metrics.

Founded in 1985 and headquartered in Ohio, STERIS maintains a critical role in the healthcare supply chain by ensuring the sterility of medical instruments and the safety of pharmaceutical production environments. The company’s integrated service model covers the entire lifecycle of medical equipment, from initial installation to outsourced instrument processing.

Headlines to Watch Out For

Elective surgery volume recovery boosts Healthcare segment demand for surgical consumables
Contract sterilization service growth tracks medical device manufacturer production cycles
Biopharmaceutical R&D spending levels dictate Life Sciences equipment and chemistry revenue
High recurring revenue from services and consumables mitigates capital equipment cyclicality
Expansion of global sterilization facility footprint drives long term AST segment margins

Piotroski VR‑10 (Strict) 8.5

Net Income: 782.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.39 > 1.0
NWC/Revenue: 21.05% < 20% (prev 17.92%; Δ 3.13% < -1%)
CFO/TA 0.12 > 3% & CFO 1.34b > Net Income 782.4m
Net Debt (1.58b) to EBITDA (1.34b): 1.17 < 3
Current Ratio: 2.09 > 1.5 & < 3
Outstanding Shares: last quarter (98.4m) vs 12m ago -0.36% < -2%
Gross Margin: 44.25% > 18% (prev 0.44%; Δ 4.38k% > 0.5%)
Asset Turnover: 56.85% > 50% (prev 53.81%; Δ 3.04% > 0%)
Interest Coverage Ratio: 8.50 > 6 (EBITDA TTM 1.34b / Interest Expense TTM 60.7m)

Altman Z'' 4.10

A: 0.12 (Total Current Assets 2.39b - Total Current Liabilities 1.15b) / Total Assets 10.74b
B: 0.27 (Retained Earnings 2.86b / Total Assets 10.74b)
C: 0.05 (EBIT TTM 515.8m / Avg Total Assets 10.44b)
D: 2.03 (Book Value of Equity 7.20b / Total Liabilities 3.54b)
Altman-Z'' Score: 4.10 = AA

Beneish M -3.09

DSRI: 0.96 (Receivables 1.09b/1.04b, Revenue 5.94b/5.46b)
GMI: 0.99 (GM 44.25% / 44.01%)
AQI: 0.94 (AQ_t 0.56 / AQ_t-1 0.59)
SGI: 1.09 (Revenue 5.94b / 5.46b)
TATA: -0.05 (NI 782.4m - CFO 1.34b) / TA 10.74b)
Beneish M-Score: -3.09 (Cap -4..+1) = AA

What is the price of STE shares? As of May 17, 2026, the stock is trading at USD 212.11 with a total of 1,387,751 shares traded.
Over the past week, the price has changed by +2.25%, over one month by -4.24%, over three months by -13.57% and over the past year by -13.22%.

Is STE a buy, sell or hold? STERIS has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold STE.

StrongBuy: 3
Buy: 2
Hold: 5
Sell: 0
StrongSell: 0

What are the forecasts/targets for the STE price?

Analysts Target Price	256.9	21.1%

STERIS (STE) - Fundamental Data Overview as of 14 May 2026

P/E Trailing = 26.6967
P/E Forward = 19.0114
P/S = 3.5004
P/B = 2.8438
P/EG = 1.5846
Revenue TTM = 5.94b USD
EBIT TTM = 515.8m USD
EBITDA TTM = 1.34b USD
Long Term Debt = 1.90b USD (from longTermDebt, two quarters ago)
Short Term Debt = 118.9m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (corrected: LT Debt 1.90b + ST Debt 118.9m)
Net Debt = 1.58b USD (recalculated: Debt 2.02b - CCE 439.6m)
Enterprise Value = 22.36b USD (20.78b + Debt 2.02b - CCE 439.6m)
Interest Coverage Ratio = 8.50 (Ebit TTM 515.8m / Interest Expense TTM 60.7m)
EV/FCF = 22.99x (Enterprise Value 22.36b / FCF TTM 972.4m)
FCF Yield = 4.35% (FCF TTM 972.4m / Enterprise Value 22.36b)
FCF Margin = 16.38% (FCF TTM 972.4m / Revenue TTM 5.94b)
Net Margin = 13.18% (Net Income TTM 782.4m / Revenue TTM 5.94b)
Gross Margin = 44.25% ((Revenue TTM 5.94b - Cost of Revenue TTM 3.31b) / Revenue TTM)
Gross Margin QoQ = 43.89% (prev 43.81%)
Tobins Q-Ratio = 2.08 (Enterprise Value 22.36b / Total Assets 10.74b)
Interest Expense / Debt = 0.75% (Interest Expense 15.1m / Debt 2.02b)
Taxrate = 27.65% (84.2m / 304.5m)
NOPAT = 373.2m (EBIT 515.8m * (1 - 27.65%))
Current Ratio = 2.09 (Total Current Assets 2.39b / Total Current Liabilities 1.15b)
Debt / Equity = 0.28 (Debt 2.02b / totalStockholderEquity, last quarter 7.20b)
Debt / EBITDA = 1.17 (Net Debt 1.58b / EBITDA 1.34b)
Debt / FCF = 1.62 (Net Debt 1.58b / FCF TTM 972.4m)
Total Stockholder Equity = 7.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.49% (Net Income 782.4m / Total Assets 10.74b)
RoE = 11.05% (Net Income TTM 782.4m / Total Stockholder Equity 7.08b)
RoCE = 5.74% (EBIT 515.8m / Capital Employed (Equity 7.08b + L.T.Debt 1.90b))
RoIC = 4.17% (NOPAT 373.2m / Invested Capital 8.94b)
WACC = 6.61% (E(20.78b)/V(22.80b) * Re(7.20%) + D(2.02b)/V(22.80b) * Rd(0.75%) * (1-Tc(0.28)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -64.41 | Cagr: -0.43%
[DCF] Terminal Value 86.28% ; FCFF base≈894.6m ; Y1≈1.10b ; Y5≈1.88b
[DCF] Fair Price = 444.8 (EV 45.21b - Net Debt 1.58b = Equity 43.63b / Shares 98.1m; r=6.61% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 82.30 | EPS CAGR: 11.21% | SUE: -0.22 | # QB: 0
Revenue Correlation: 81.36 | Revenue CAGR: 8.83% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.50 | Chg30d=+0.38% | Revisions=-20% | Analysts=7
EPS next Quarter (2026-09-30): EPS=2.69 | Chg30d=-0.10% | Revisions=+20% | Analysts=7
EPS current Year (2027-03-31): EPS=11.15 | Chg30d=+0.59% | Revisions=-27% | GrowthEPS=+9.6% | GrowthRev=+7.2%
EPS next Year (2028-03-31): EPS=12.10 | Chg30d=-0.31% | Revisions=+0% | GrowthEPS=+8.5% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -27%